175 related articles for article (PubMed ID: 34997365)
21. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
[TBL] [Abstract][Full Text] [Related]
22. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
[TBL] [Abstract][Full Text] [Related]
23. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer.
Kim HA; Seong MK; Kim JH; Kim YG; Choi HS; Kim JS; Park IC; Jin HO; Lee JK; Noh WC
Anticancer Res; 2016 Mar; 36(3):1051-7. PubMed ID: 26976997
[TBL] [Abstract][Full Text] [Related]
25. Correlation between sonographic and endocrine markers of ovarian aging as predictors for late menopausal transition.
Yang YS; Hur MH; Kim SY; Young K
Menopause; 2011 Feb; 18(2):138-45. PubMed ID: 21341396
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
[TBL] [Abstract][Full Text] [Related]
27. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women.
Dunlop CE; Anderson RA
Maturitas; 2015 Mar; 80(3):245-50. PubMed ID: 25596814
[TBL] [Abstract][Full Text] [Related]
28. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.
Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T
J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154
[TBL] [Abstract][Full Text] [Related]
29. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
30. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
31. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
[TBL] [Abstract][Full Text] [Related]
32. Can Anti-Müllerian Hormone Be a Reliable Biomarker for Assessing Ovarian Function in Women Postchemotherapy?
Li X; Liu S; Ma L; Chen X; Weng H; Huang R; Yu Y; Zong X
Cancer Manag Res; 2020; 12():8171-8181. PubMed ID: 32982414
[TBL] [Abstract][Full Text] [Related]
33. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
[TBL] [Abstract][Full Text] [Related]
34. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
35. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
36. Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.
Eliassen AH; Zeleniuch-Jacquotte A; Rosner B; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2016 May; 25(5):854-60. PubMed ID: 26961996
[TBL] [Abstract][Full Text] [Related]
37. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review.
Nelson SM; Davis SR; Kalantaridou S; Lumsden MA; Panay N; Anderson RA
Hum Reprod Update; 2023 May; 29(3):327-346. PubMed ID: 36651193
[TBL] [Abstract][Full Text] [Related]
38. Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal Women.
Clendenen TV; Ge W; Koenig KL; Afanasyeva Y; Agnoli C; Bertone-Johnson E; Brinton LA; Darvishian F; Dorgan JF; Eliassen AH; Falk RT; Hallmans G; Hankinson SE; Hoffman-Bolton J; Key TJ; Krogh V; Nichols HB; Sandler DP; Schoemaker MJ; Sluss PM; Sund M; Swerdlow AJ; Visvanathan K; Liu M; Zeleniuch-Jacquotte A
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4542-e4553. PubMed ID: 34157104
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle.
Lin PY; Huang FJ; Kung FT; Chiang HJ; Lin YJ; Lin YC; Lan KC
Int J Clin Exp Pathol; 2014; 7(9):6245-53. PubMed ID: 25337276
[TBL] [Abstract][Full Text] [Related]
40. Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels : anti-Müllerian hormone in poor responders in assisted reproductive treatment.
Celik H; Bıldırcın D; Güven D; Cetinkaya MB; Alper T; Batuoğlu AS
J Assist Reprod Genet; 2012 Aug; 29(8):797-802. PubMed ID: 22573035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
